Even though the limited and heterogeneous literature about lactoferrin supplementation in COVID-19 patients prevents the possibility of elaborating clear clinical guidelines on this topic, the good profile of safety and tolerability of this compound fosters new clinical trials designed and powered to evaluate lactoferrin effectiveness in improving COVID-19 clinical evolution, especially considering the high mutation rate of the SARS-CoV-2 viral agent and the proven antiviral activity of this nutritional supplement against the new emerging viral variants [30,65,70]. The gene discussed is LTF; the disease is COVID-19.